NAFLD-related hepatocellular carcinoma: The growing challenge.

Authors:
Shah PA; Patil R; Harrison SA.

Journal:
Hepatology

Publication Year: 2022

DOI:
10.1002/hep.32542

PMCID:
PMC9970023

PMID:
35478412

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Hepatology

Abbreviation: Hepatology

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A global action agenda for turning the tide on fatty liver disease.
Lazarus JV; Mark HE; Allen AM and 44 more (2023) - Transparency Score: 3/6
c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.
Leslie J; Hunter JE; Collins A and 15 more (2023) - Transparency Score: 3/6
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex wi…
Mizushima D; Takano M; Aoki T and 7 more (2023) - Transparency Score: 3/6
Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hep…
Gömer A; Klöhn M; Jagst M and 12 more (2023) - Transparency Score: 3/6
Enhanced mitochondrial activity reshapes a gut microbiota profile that delays NASH progression.
Juárez-Fernández M; Goikoetxea-Usandizaga N; Goikoetxea-Usandizaga N and 18 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICTS OF INTEREST Dr. Harrison owns stock in Akero Therapeutics, Galectin Therapeutics, Genfit Corp, Hepion Pharmaceuticals, Metactine, NGM Biopharmaceuticals, Chronwell, Cirius Therapeutics, and HistoIndex. Dr. Harrison consults for and advises Altimmune, Alimentiv, Akero Therapeutics, Axcella Pharmaceuticals, Boston Pharmaceuticals, Echosens North America, Enyo Pharma S.A., Galectin Therapeutics, Genfit Corp, Gilead Sciences, Hepion Pharmaceuticals, Medpace, Metacrine, NGM Biopharmaceuticals, Novartis, Northsea Therapeutics, Cirius Therapeutics, HistoIndex, Hightide Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, PathAI, Perspectum Diagnostics, Poxel, Sagimet Biosciences, Sonic Incytes, Terns, and Viking. Dr. Harrison has received grants from Altimmune, Akero, Axcella Pharmaceuticals, Boehringer Ingelheim, Corcept Therapeutics, Enyo Pharma S.A., Ionis, 89Bio, Galectin, Gilead, Genfit, Hepion Therapeutics, Intercept, Madrigal Pharmaceuticals, Novo Nordisk, Novartis, NGM Biopharmaceuticals, Poxel, Sagimet Biosciences, Viking."

Evidence found in paper:

"CONFLICTS OF INTERESTDr. Harrison owns stock in Akero Therapeutics, Galectin Therapeutics, Genfit Corp, Hepion Pharmaceuticals, Metactine, NGM Biopharmaceuticals, Chronwell, Cirius Therapeutics, and HistoIndex. Dr. Harrison consults for and advises Altimmune, Alimentiv, Akero Therapeutics, Axcella Pharmaceuticals, Boston Pharmaceuticals, Echosens North America, Enyo Pharma S.A., Galectin Therapeutics, Genfit Corp, Gilead Sciences, Hepion Pharmaceuticals, Medpace, Metacrine, NGM Biopharmaceuticals, Novartis, Northsea Therapeutics, Cirius Therapeutics, HistoIndex, Hightide Therapeutics, Intercept Pharmaceuticals, Madrigal Pharmaceuticals, Novo Nordisk, PathAI, Perspectum Diagnostics, Poxel, Sagimet Biosciences, Sonic Incytes, Terns, and Viking. Dr. Harrison has received grants from Altimmune, Akero, Axcella Pharmaceuticals, Boehringer Ingelheim, Corcept Therapeutics, Enyo Pharma S.A., Ionis, 89Bio, Galectin, Gilead, Genfit, Hepion Therapeutics, Intercept, Madrigal Pharmaceuticals, Novo Nordisk, Novartis, NGM Biopharmaceuticals, Poxel, Sagimet Biosciences, Viking."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025